NCT04372992 (STOMAD) is a NA clinical trial of Timing of stoma closure in Ileostomy, sponsored by Ospedale Umberto I di Torino.

Who is sponsoring NCT04372992?

NCT04372992 is sponsored by Ospedale Umberto I di Torino.

What drugs are being tested in NCT04372992?

Interventions in NCT04372992: Timing of stoma closure.

What condition does NCT04372992 study?

NCT04372992 studies Ileostomy, Rectal Cancer.

Is NCT04372992 still recruiting?

NCT04372992 is currently terminated. Last updated 22 September 2022.

Last reviewed 2022-09-22 · How we verify

NCT04372992: STOMAD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Stoma Closure Before or After Adjuvant Therapy Trial

Terminated NA Last updated 22 September 2022

What this trial tests

NA trial testing Timing of stoma closure in Ileostomy in 14 participants. Terminated before completion.

Timeline

1 September 2020

Primary endpoint
1 September 2022

1 September 2022

Quick facts

Lead sponsor	Ospedale Umberto I di Torino
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	health services research
Enrollment	14
Start date	1 September 2020
Primary completion	1 September 2022
Estimated completion	1 September 2022
Sites	28 locations across Italy

Drugs / interventions tested

Timing of stoma closure

Conditions studied

Ileostomy — all drugs for Ileostomy →
Rectal Cancer — all drugs for Rectal Cancer →

Sponsor

Ospedale Umberto I di Torino

Who can join

18 and older, any sex, with Ileostomy or Rectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open-label multicenter controlled trial, including 28 centers from the Rete Oncologica (Oncological Network) of Piemonte and Valle d'Aosta in Italy (http://www.reteoncologica.it). After a curative resection for rectal cancer and temporary ileostomy, 270 patients with indication to adjuvant chemotherapy will be randomized to early (before starting adjuvant treatment) or late (after adjuvant treatment completion) stoma closure. Primary end point will the compliance to adjuvant therapy. Secondary endpoint will include quality of life and bowel function evaluation, postoperative morbidity, chemotherapy toxicity, oncological outcomes and costs comparison.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Prospective, randomised, multicentre, open-label trial, designed to evaluate the best timing of closure of the temporary ileostomy (early versus late) in patients who underwent rectal cancer resection and with indication for adjuvant chemotherapy: the STOMAD (STOMa closure before
Massucco P, Fontana A, Mineccia M, Perotti S, et al · · 2021 · cited 10× · PMID 33608405 · DOI 10.1136/bmjopen-2020-044692
Characteristics of Interventional Trials for Patients Living With Intestinal Stoma Registered in ClinicalTrials.gov With a Focus on Inflammatory Bowel Disease.
Vuyyuru SK, Ma C, Sharma T, Nguyen TM, et al · · 2024 · cited 3× · PMID 38135729 · DOI 10.1093/ibd/izad293

Verify or expand the search:

Other recruiting trials for Ileostomy

Currently open trials in the same condition.

NCT06604052 — A Study Comparing Laparoscopic/Robotic Stoma Reduced-Port Fusion Surgery with Traditional Surgery in Patients with Tempo · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04372992 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ospedale Umberto I di Torino
Last refreshed: 22 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04372992.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing